Laboratorio museotecnico Goppion

Laboratorio Curie Expands Relationship with SOPHiA GENETICS

Retrieved on: 
Wednesday, September 13, 2023
Database, Lab, NGS, Cancer, Breast, Research, Genomics, Sophia, Sophia Genetics, Trust, Risk, Medicine, GENETICS, Laboratorio museotecnico Goppion, Artificial intelligence, BRCA, Hand, Pharmaceutical industry, Antibiotics

BOSTON and ROLLE, Switzerland, Sept. 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, has expanded its relationship with Laboratorio Curie, a leading laboratory located in the capital city of Paraguay. Laboratorio Curie is now live on the SOPHiA DDM™ Platform and will use the technology to deploy a new test that will identify BRCA gene mutations. Discoveries made using this test aim to enable Laboratorio Curie to support the increased use of precision medicine for hereditary cancers within the country.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Sept. 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, has expanded its relationship with Laboratorio Curie, a leading laboratory located in the capital city of Paraguay.
  • Laboratorio Curie is now live on the SOPHiA DDM™ Platform and will use the technology to deploy a new test that will identify BRCA gene mutations.
  • Since 2022 the Lab has worked with SOPHiA GENETICS to examine variants associated with hereditary cancers and the expansion of its relationship with SOPHiA GENETICS will allow the Lab to advance its existing research.
  • "By using the SOPHiA DDM™ Platform, Laboratorio Curie can ensure speed and accuracy of its NGS testing to best support investigations into BRCA-associated cancers.

Knight to Present at Stifel Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Nature, Laboratorio museotecnico Goppion, Intention, Therapy, Annual report, Conference, TSX, Lotte New York Palace Hotel, GUD, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

Retrieved on: 
Monday, August 15, 2022
Parkinson's disease, Internal medicine, Dementia, GLOBE, GUD, TSX, Rivastigmine, National university, Annual report, Caregiver, Marketing, Patient, Therapy, Acquisition, Alzheimer's disease, Associate, Nature, Intention, Federal University of Minas Gerais, Laboratorio museotecnico Goppion, UFMG, Pharmaceutical industry, Exelon, Novartis, Uniting Medically Supervised Injecting Centre, Knight

MONTREAL, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon (rivastigmine) in Brazil following successful transfer of the marketing authorization.

Key Points: 
  • MONTREAL, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon (rivastigmine) in Brazil following successful transfer of the marketing authorization.
  • Exelon is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries.
  • Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Axo Entertainment Group Announces Saving Axolotls from Extinction with Non Fungible Tokens

Retrieved on: 
Tuesday, June 14, 2022
Health, Consumer, Environment, Technology, Other Technology, Hispanic, Veterinary, Sale, Landmark Entertainment Group, LRE, Axolotl, NFT, Research, Laboratorio museotecnico Goppion, Education, Non-fungible token, Parent, Nightclub

Axo Entertainment Group (Toronto, Ontario) and Dr. Luis Zambrano, biologist at Laboratorio de Restauracin Ecolgica (LRE) have joined forces to assist in the preservation and recovery of axolotls in their native Mexican habitat.

Key Points: 
  • Axo Entertainment Group (Toronto, Ontario) and Dr. Luis Zambrano, biologist at Laboratorio de Restauracin Ecolgica (LRE) have joined forces to assist in the preservation and recovery of axolotls in their native Mexican habitat.
  • Axolotls, of the salamander family, are near extinction in their homeland and require funding for research and conservation programs in an effort to improve the Mexican ecosystem as a whole.
  • Axo Entertainment Group will issue a limited number of non-fungible tokens (NFTs) on June 16, 2022 in support of the cause.
  • Twenty-five percent of the profits from the sale of NFTs and associated royalty streams will be donated to Dr. Zambrano's organization to accelerate the preservation of axolotls.

Saving Axolotls from Extinction with Non Fungible Tokens

Retrieved on: 
Monday, June 13, 2022
Research, Laboratorio museotecnico Goppion, Non-fungible token, MEXICO, Axolotl, LRE, NFT, Sale, Parent, CITY, Education, Nightclub

Axolotls, of the salamander family, are near extinction in their homeland and require funding for research and conservation programs in an effort to improve the Mexican ecosystem as a whole.

Key Points: 
  • Axolotls, of the salamander family, are near extinction in their homeland and require funding for research and conservation programs in an effort to improve the Mexican ecosystem as a whole.
  • Axo Entertainment Group will issue a limited number of non-fungible tokens (NFTs) on June 16, 2022 in support of the cause.
  • Twenty-five percent of the profits from the sale of NFTs and associated royalty streams will be donated to Dr. Zambrano's organization to accelerate the preservation of axolotls.
  • To learn about Dr. Zambrano's passion for preservation of the axolotl see his Ted Talk at https://www.youtube.com/watch?v=hccblbdXXuU .

Knight to Present at the Jefferies 2022 Healthcare Conference in New York City

Retrieved on: 
Friday, June 3, 2022
Conference, Laboratorio museotecnico Goppion, Pan-American, Annual report, Nature, GUD, Therapy, GLOBE, TSX, Intention, Generic drug, Uniting Medically Supervised Injecting Centre

MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City.

Key Points: 
  • MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia

Retrieved on: 
Wednesday, June 1, 2022
Laboratorio museotecnico Goppion, Marketing, Annual report, Nature, GUD, Rivastigmine, Parkinson's disease, Therapy, GLOBE, Acquisition, TSX, Dementia, Alzheimer's disease, Intention, Pharmaceutical industry, Uniting Medically Supervised Injecting Centre, Knight, Exelon, Novartis

MONTREAL, June 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon (rivastigmine) in Colombia upon successful transfer of the marketing authorization.

Key Points: 
  • MONTREAL, June 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon (rivastigmine) in Colombia upon successful transfer of the marketing authorization.
  • Exelon is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries.
  • "We are excited to assume full commercial activities of Exelon in Colombia and continue to support this well established and important therapy option in an area of such high unmet need as Alzheimer's," said Samira Sakhia, President & Chief Executive Officer of Knight.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight to Present at the 2022 RBC Capital Markets Global Healthcare Conference in New York City

Retrieved on: 
Thursday, May 12, 2022
InterContinental New York Barclay Hotel, GUD, Therapy, Nature, TSX, Intention, Conference, Laboratorio museotecnico Goppion, Annual report, GLOBE, Uniting Medically Supervised Injecting Centre

MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 at 8:30 am ET at the InterContinental New York Barclay hotel in New York City.

Key Points: 
  • MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 at 8:30 am ET at the InterContinental New York Barclay hotel in New York City.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight Therapeutics Inc. announces voting results from the Annual Meeting

Retrieved on: 
Thursday, May 12, 2022
TSX, Intention, GUD, Laboratorio museotecnico Goppion, Therapy, Nature, Annual report, Generic drug, Security (finance), Pharmaceutical industry, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.

Key Points: 
  • Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call

Retrieved on: 
Thursday, May 5, 2022
GUD, Annual report, TSX, Laboratorio museotecnico Goppion, Nature, Therapy, Intention, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.